RxDoctor Payments Data

Daniela Chiriboga Salazar, MD

Internal Medicine · Jacksonville, FLNPI 1720273865

Payments from drug & device makers

$322,127in general payments, 2019–2025

Across 436 payments — averaging $738.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$308K
  • Merck$6K
  • Gilead$6K
  • Theratechnologies Inc.$715
  • AbbVie$256
  • EMD Serono, Inc.$213
  • plus $349 from 5 others

What the payments were for

  • Consulting fees$21,73619%
  • Speaking & faculty fees$73,88063%
  • Travel & lodging$11,58210%
  • Food & beverage$9,4278%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$322,127 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$4,156
Medicare patients
32
Services billed
52

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala357$1,410,428
DovatoDolutegravir Sodium/Lamivudine114$343,244
TivicayDolutegravir Sodium111$250,183
JulucaDolutegravir/Rilpivirine45$161,799
CabenuvaCabotegravir/Rilpivirine27$152,892
RukobiaFostemsavir Tromethamine13$123,057
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf26$119,697
DescovyEmtricitabine/Tenofov Alafenam51$107,720
GenvoyaElviteg/Cob/Emtri/Tenof Alafen24$92,279
PrezcobixDarunavir/Cobicistat37$85,779
PifeltroDoravirine29$49,244
JardianceEmpagliflozin13$14,932
LyricaPregabalin12$12,349
Ventolin HfaAlbuterol Sulfate22$1,600
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen30$851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$5,931$1,610,427432 claims
Viiv Healthcare CompanyDovato, Tivicay, Juluca, Cabenuva, Rukobia$308,330$1,031,176310 claims
Johnson & JohnsonPrezcobix$202$85,77937 claims
MerckPifeltro$6,332$49,24429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →